4.6 Review

Net Survival in Survival Analyses for Patients with Cancer: A Scoping Review

Journal

CANCERS
Volume 14, Issue 14, Pages -

Publisher

MDPI
DOI: 10.3390/cancers14143304

Keywords

cancer survival; net survival; cancer registries; epidemiology; Pohar Perme Estimator

Categories

Funding

  1. Coordination for the Improvement of Higher Education Personnel-CAPES [1973/2016]
  2. Internal Scholarship Program of the State University of Southwest Bahia-UESB

Ask authors/readers for more resources

This scoping review examines the use and justifications of the Pohar Perme Estimator (PPE) in estimating net survival in oncology. The review finds that PPE is recognized as the gold standard for estimating net survival and is valued for its unbiased estimates and comparability among different populations. No limitations of using PPE are identified. The review concludes that PPE should be more widely used in oncology, especially for population-based studies with long follow-up time.
Simple Summary The Pohar Perme Estimator (PPE) is the gold standard for estimating net survival, however, few studies in the field of oncology have used this estimator. The PPE was identified as an important epidemiological indicator, which is easy to implement, produces unbiased estimates of net survival and allows comparison of survival between different populations. This scope review aims to clarify the potential benefits of the Pohar Perme Estimator for calculating the net survival of patients diagnosed with cancer and the justifications presented in the literature regarding the use, approach and application of the method. With this review, we recognize the importance of PPE in the field of oncology and we hope that it will be more used in the analysis of net survival, aiming to establish control strategies and improve the survival of these patients. Population-based net survival is an important tool for assessing prognostic advances. The unbiased Pohar Perme Estimator (PPE) was suggested in 2012 and soon established itself as the gold standard for estimating net survival. This scoping review aims to know in which context this estimator is being used in the oncology area, what the authors point out as a justification for its use, and the limitations found. We searched PubMed, and the grey literature to answer the question: Have studies involving patients diagnosed with cancer used the PPE to estimate cancer-specific survival? How do they justify the use of the PPE and what are the limitations pointed out? Out of 295 screened, 85 studies were included in this review. The two main characteristics of the PPE mentioned by the studies as justification were the fact that it is an unbiased estimator (83.5%) and that it produces comparable estimates among populations with different mortality rates from causes other than cancer (36.47%). No study pointed to a limitation due to the use of PPE. As a conclusion, the Pohar Perme Estimator is the gold standard for estimating net survival and should be more used in oncology, especially when dealing with population-based studies where the follow-up time is long, making high the probability of death from causes other than cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available